protein

Recombinant Human HLA class II histocompatibility antigen, DR alpha chain (HLA-DRA)

MBS1093239

0.05 mg (E-Coli)

180 USD

Recombinant Protein

Recombinant Human HLA class II histocompatibility antigen, DR alpha chain (HLA-DRA)

HLA class II histocompatibility antigen, DR alpha chain (HLA-DRA)

HLA class II histocompatibility antigen, DR alpha chain; MHC class II antigen DRA

HLA class II histocompatibility antigen, DR alpha chain; HLA class II histocompatibility antigen, DR alpha chain; HLA class II histocompatibility antigen, DR alpha chain; MHC class II antigen DRA; MHC cell surface glycoprotein; histocompatibility antigen HLA-DR alpha; major histocompatibility complex, class II, DR alpha; MHC class II antigen DRA

HLA-DRA

HLA-DRA; HLA-DRA1

HLA-DRA; HLA-DRA; MLRW; HLA-DRA1; HLA-DRA1

DRA_HUMAN

E Coli or Yeast or Baculovirus or Mammalian Cell

26-254, Mature full length protein.

254

IKEEHVIIQAEFYLNPDQSGEFMFDFDGDEIFHVDMAKK
ETVWRLEEFGRFASFEAQGALANIAVDKANLEIMTKRSN
YTPITNVPPEVTVLTNSPVELREPNVLICFIDKFTPPVV
NVTWLRNGKPVTTGVSETVFLPREDHLFRKFHYLPFLPS
TEDVYDCRVEHWGLDEPLLKHWEFDAPSPLPETTENVVC
ALGLTVGLVGIIIGTIFIIKGVRKSNAAERRGPL

>90%

Liquid containing glycerol; lyophilization may be available upon request.

Store at -20 degrees C. For long-term storage, store at -20 degrees C or -80 degrees C. Store working aliquots at 4 degrees C for up to one week. Repeated freezing and thawing is not recommended.

Species: Homo sapiens (Human)

Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) and presents them on the cell surface for recognition by the CD4 T-cells. The peptide binding cleft accommodates peptides of 10-30 residues. The peptides presented by MHC class II molecules are generated mostly by degradation of proteins that access the endocytic route, where they are processed by lysosomal proteases and other hydrolases. Exogenous antigens that have been endocytosed by the APC are thus readily available for presentation via MHC II molecules, and for this reason this antigen presentation pathway is usually referred to as exogenous. As membrane proteins on their way to degradation in lysosomes as part of their normal turn-over are also contained in the endosomal/lysosomal compartments, exogenous antigens must compete with those derived from endogenous components. Autophagy is also a source of endogenous peptides, autophagosomes constitutively fuse with MHC class II loading compartments. In addition to APCs, other cells of the gastrointestinal tract, such as epithelial cells, express MHC class II molecules and CD74 and act as APCs, which is an unusual trait of the GI tract. To produce a MHC class II molecule that presents an antigen, three MHC class II molecules (heterodimers of an alpha and a beta chain) associate with a CD74 trimer in the ER to form a heterononamer. Soon after the entry of this complex into the endosomal/lysosomal system where antigen processing occurs, CD74 undergoes a sequential degradation by various proteases, including CTSS and CTSL, leaving a small fragment termed CLIP (class-II-associated invariant chain peptide). The removal of CLIP is facilitated by HLA-DM via direct binding to the alpha-beta-CLIP complex so that CLIP is released. HLA-DM stabilizes MHC class II molecules until primary high affinity antigenic peptides are bound. The MHC II molecule bound to a peptide is then transported to the cell membrane surface. In B-cells, the interaction between HLA-DM and MHC class II molecules is regulated by HLA-DO. Primary dendritic cells (DCs) also to express HLA-DO. Lysosomal miroenvironment has been implicated in the regulation of antigen loading into MHC II molecules, increased acidification produces increased proteolysis and efficient peptide loading.

52426774

NP_061984.2

NM_019111.4

P01903

28,607 Da

Adaptive Immune System Pathway (366160); Allograft Rejection Pathway (83123); Allograft Rejection Pathway (535); Antigen Processing And Presentation Pathway (83074); Antigen Processing And Presentation Pathway (485); Asthma Pathway (83120); Asthma Pathway (532); Autoimmune Thyroid Disease Pathway (83121); Autoimmune Thyroid Disease Pathway (533); CXCR4-mediated Signaling Events Pathway (137910)

HLA-DRA is one of the HLA class II alpha chain paralogues. This class II molecule is a heterodimer consisting of an alpha and a beta chain, both anchored in the membrane. It plays a central role in the immune system by presenting peptides derived from extracellular proteins. Class II molecules are expressed in antigen presenting cells (APC: B lymphocytes, dendritic cells, macrophages). The alpha chain is approximately 33-35 kDa and its gene contains 5 exons. Exon 1 encodes the leader peptide, exons 2 and 3 encode the two extracellular domains, and exon 4 encodes the transmembrane domain and the cytoplasmic tail. DRA does not have polymorphisms in the peptide binding part and acts as the sole alpha chain for DRB1, DRB3, DRB4 and DRB5. [provided by RefSeq, Jul 2008]

HLA-DRA: Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) and presents them on the cell surface for recognition by the CD4 T-cells. The peptide binding cleft accommodates peptides of 10-30 residues. The peptides presented by MHC class II molecules are generated mostly by degradation of proteins that access the endocytic route, where they are processed by lysosomal proteases and other hydrolases. Exogenous antigens that have been endocytosed by the APC are thus readily available for presentation via MHC II molecules, and for this reason this antigen presentation pathway is usually referred to as exogenous. As membrane proteins on their way to degradation in lysosomes as part of their normal turn-over are also contained in the endosomal/lysosomal compartments, exogenous antigens must compete with those derived from endogenous components. Autophagy is also a source of endogenous peptides, autophagosomes constitutively fuse with MHC class II loading compartments. In addition to APCs, other cells of the gastrointestinal tract, such as epithelial cells, express MHC class II molecules and CD74 and act as APCs, which is an unusual trait of the GI tract. To produce a MHC class II molecule that presents an antigen, three MHC class II molecules (heterodimers of an alpha and a beta chain) associate with a CD74 trimer in the ER to form a heterononamer. Soon after the entry of this complex into the endosomal/lysosomal system where antigen processing occurs, CD74 undergoes a sequential degradation by various proteases, including CTSS and CTSL, leaving a small fragment termed CLIP (class-II-associated invariant chain peptide). The removal of CLIP is facilitated by HLA-DM via direct binding to the alpha-beta-CLIP complex so that CLIP is released. HLA-DM stabilizes MHC class II molecules until primary high affinity antigenic peptides are bound. The MHC II molecule bound to a peptide is then transported to the cell membrane surface. In B-cells, the interaction between HLA-DM and MHC class II molecules is regulated by HLA-DO. Primary dendritic cells (DCs) also to express HLA-DO. Lysosomal miroenvironment has been implicated in the regulation of antigen loading into MHC II molecules, increased acidification produces increased proteolysis and efficient peptide loading. Belongs to the MHC class II family. Protein type: Membrane protein, integral. Chromosomal Location of Human Ortholog: 6p21.3. Cellular Component: Golgi membrane; cell surface; lysosome; late endosome membrane; lysosomal membrane; integral to plasma membrane; plasma membrane; trans-Golgi network membrane; MHC class II protein complex. Molecular Function: MHC class II receptor activity; peptide antigen binding. Biological Process: peptide antigen assembly with MHC class II protein complex; cytokine and chemokine mediated signaling pathway; T cell costimulation; antigen processing and presentation of exogenous peptide antigen via MHC class II; immune response; cognition; T cell receptor signaling pathway; polysaccharide assembly with MHC class II protein complex; antigen processing and presentation of peptide or polysaccharide antigen via MHC class II. Disease: Hepatitis B Virus, Susceptibility To

0.05 mg (E-Coli)

180 USD

0.2 mg (E-Coli)

490

0.5 mg (E-Coli)

715

0.05 mg (Baculovirus)

950

1 mg (E-Coli)

1170